Summa Equity, a private equity firm, completed the acquisition of Axion BioSystems, a US life science tools business specializing in the development, production, and marketing of MEA and impedance technologies. Financial terms were not disclosed. "Summa has been focused on solutions in the CGT market for a long period of time, due to its alignment with our strategy and its significant potential for growth. Axion BioSystems impressed us with its market-leading, highly competitive and scalable technology, which gives both academics and biopharma organisations the ability to go much deeper in their understanding of cell behaviour, enabling faster, more accurate and more cost-efficient drug discovery, development and quality control. We look forward to working with the team as it continues to develop its technology and grow its market share, while continuing to solve some of society’s biggest pharmaceutical and healthcare challenges," Tommi Unkuri, Summa Equity Partner.